- Source type
- Trial registry
- Access type
- Official
- Publisher
- ClinicalTrials.gov
- Date
- 2026
- Added
- 2026-06-30
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
84
Clinical trial registry
- Publisher type
- Trial registry
- Bias profile
- Moderate
This source is strongest for trial discovery and safety and weaker for mechanism and consumer context.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 64/100
- Context Source
- Clinical outcomes
- 67/100
- Context Source
- Mechanism
- 64/100
- Context Source
- Safety
- 71/100
- Context Source
- Consumer context
- 64/100
- Context Source
- Trial discovery
- 92/100
- Primary Anchor
Best used for
- Trial status
- Protocol and endpoint discovery
Weak for
- Unpublished results
- Clinical conclusions
Used in Viral Vitalism
Epigenetic Gene Therapy Shows Early Muscle Gains in FSHD Patients
Roles: Background
Related studies
No structured study record is currently attached to this source.
Related sources
UCSF Clinical Trials: NGN-401 Rett syndrome study
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- UCSF Clinical Trials
- Access
- Publisher
- Usage
- 1 connection
ClinicalTrials.gov: PROPEL 3 study NCT06164951
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
ClinicalTrials.gov: Safety and Efficacy of PTH-IA
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
ClinicalTrials.gov: KIO-301 ABACUS-1 trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 0 connections
ClinicalTrials.gov: ReMIND trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
FDA: Draft Guidance to Help Accelerate Cell and Gene Therapies
Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection